Elon Musk and Sam Altman reignited their feud over AI safety, space data centers and allegations of trade-secret theft.

Rep. Ro Khanna said Israeli settlers carrying American-made M4 rifles detained him and other Americans during a visit to the West Bank. In a Saturday post on X, Khanna said when Israeli Defense Forces ...

Web site created using create-react-app U.S. stock futures were mixed this morning, with the Dow futures gaining around 100 points on Friday. Shares of Fermi Inc (NASDAQ: FRMI) fell sharply in ...

On Friday, Meta updated its blog post and said it has removed the AI feature introduced earlier this week as part of Muse Image, the company’s first image-generation model from Meta Superintelligence ...

Nvidia ‘s (NASDAQ: NVDA) stock price has staged a strong comeback, a few days after it moved to a local bear market. NVDA jumped to $210 on Friday, up by 10% from its lowest level this month. It has ...

Each week, Benzinga’s Stock Whisper Index uses a combination of proprietary data and pattern recognition to showcase five stocks that are just under the surface and deserve attention. Investors are ...

Benzinga examined the prospects for many investors’ favorite stocks over the last week — here’s a look at some of our top stories. U.S. stocks finished the week with solid gains as technology shares ...

Catheter Precision, Inc. (NYSE: VTAK) shares plummeted on Friday as traders reversed part of the stock’s recent headline-driven gains tied to its Flyte subsidiary and new patent announcements. The ...

Weak Stock, Strong Fundamentals On Thursday, before the market opened, CCC announced it will release its financial results for the second quarter ended Jun. 30. In the last quarter, reported in April, ...

Rackspace is shifting focus to AI outcomes rather than raw GPU capacity. CFO Mark Marino shares their strategy and ...

Lucid Group Inc (NASDAQ: LCID) shares are trading marginally higher on Thursday as investors digest a fresh round of operational and leadership updates after the company detailed Q2 production and ...

FDA approves Pfizer and Astellas' PADCEV plus Keytruda for muscle-invasive bladder cancer, backed by Phase 3 survival data.